NCT06046950Active, not recruiting
TrEatment Targets in Rheumatoid Arthritis: TETRA-study
TrEatment Targets in Rheumatoid Arthritis: a Randomized Multi-centre, Treat to Target Strategy Trial: TETRA Study
Source: ClinicalTrials.gov · Last updated 11 Sept 2025
Brief summary (registry, in English)
There is currently no cure for rheumatoid arthritis (RA), but many treatment options are available. The central aim of RA treatment is lowering disease activity. The proactive treatment strategy called treat to target (T2T) includes measuring disease activity, setting a target and adjusting treatment accordingly until the goal is reached. T2T has proven to be superior to usual care, but there is much debate regarding the most optimal treatment measure and target. The Disease Activity Score with 28-joint counts and c-reactive protein (DAS28CRP) low-disease activity (LDA) target and the more stringent Simplified Disease Activity Index (SDAI) remission target are the best validated targets. Especially the DAS28CRP is the most commonly used in research and practice, whereas the SDAI remission target is most recommended. The European Alliance of Associations for Rheumatology (EULAR) recommends to strive for remission, whereas the American College of Rheumatology (ACR) recommends to strive for LDA. In patients with new and established RA, the (cost)effectiveness of aiming for remission compared to LDA when starting and tapering antirheumatic drugs has not been directly compared. This study therefore aims to directly compare two T2T strategies, aiming at DAS28CRP-LDA and SDAI remission, in patients with established RA.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 340 (estimated)
- First submitted
- 15 Aug 2023
- Start date
- 20 Dec 2023
- Primary completion date
- Feb 2027
- Lead sponsor
- Sint Maartenskliniek
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT06046950
What you commit to
- Study type: Interventional
- Planned participants: 340
- From 20 Dec 2023 to the primary completion date, Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Current severe comorbidity or other serious life-shortening conditions hampering trial participation
Other
- Clinical deep remission, operationalised as SDAI \<3.3 or DAS28-CRP \<2.4, and an taper attempt in the past 2 years that was discontinued due to occurrence of flare.
- Fewer than 3 DMARD treatment options left for this patient (severe difficult-to-treat or refractory RA)
- Inability to comply with the study protocol or to provide informed consent with regard to intervention control and measuring outcomes
Who the study is looking for
- Diagnosis of RA (according to the 2010 or 1987 ACR/ EULAR classification criteria and/or clinical diagnosis)
- (Starting) use of a DMARD
- Aged 16 years or older
- At most low disease activity, operationalised as DAS28-CRP \<3.5 (DAS28 CRP 2.9 cut off for low disease activity with measurement error 0.6) or SDAI \<19 (SDAI 11 cut off for low disease activity with measurement error of 8). A state of low disease activity is required at inclusion, as for RA patients in moderate or high disease activity there is no equipoise on the best course of action (treatment needs to be escalated).
- Fluency of Dutch or English, both written and verbally; able to fill in questionnaires
- Provided informed consent
Age in the registry: 16 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sint Maartenskliniek Coordinator of this site? Confirm its status | Ubbergen | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.